

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6200040

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	BIOELECTRON TECHNOLOGY CORPORATION	10/25/2019
RECEIVING PARTY DATA		
Name:	PTC THERAPEUTICS, INC.	
Street Address:	100 CORPORATE COURT	
City:	SOUTH PLAINFIELD	
State/Country:	NEW JERSEY	
Postal Code:	07080-2449	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	11445582
CORRESPONDENCE DATA		
Fax Number:	(415)393-9887	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(415) 954-0200	
Email:	tanisha.lawrence-caceres@squirepb.com	
Correspondent Name:	SQUIRE PATTON BOGGS (US) LLP	
Address Line 1:	275 BATTERY STREET, SUITE 2600	
Address Line 2:	ATTN: JANICE V. RICE	
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94111	
ATTORNEY DOCKET NUMBER:	112738.00006	
NAME OF SUBMITTER:	JANICE V. RICE	
SIGNATURE:	/Janice V. Rice/	
DATE SIGNED:	07/14/2020	
Total Attachments: 41		
source=Patent Assignment#page1.tif		
source=Patent Assignment#page2.tif		
source=Patent Assignment#page3.tif		
source=Patent Assignment#page4.tif		
source=Patent Assignment#page5.tif		

source=Patent Assignment#page6.tif
source=Patent Assignment#page7.tif
source=Patent Assignment#page8.tif
source=Patent Assignment#page9.tif
source=Patent Assignment#page10.tif
source=Patent Assignment#page11.tif
source=Patent Assignment#page12.tif
source=Patent Assignment#page13.tif
source=Patent Assignment#page14.tif
source=Patent Assignment#page15.tif
source=Patent Assignment#page16.tif
source=Patent Assignment#page17.tif
source=Patent Assignment#page18.tif
source=Patent Assignment#page19.tif
source=Patent Assignment#page20.tif
source=Patent Assignment#page21.tif
source=Patent Assignment#page22.tif
source=Patent Assignment#page23.tif
source=Patent Assignment#page24.tif
source=Patent Assignment#page25.tif
source=Patent Assignment#page26.tif
source=Patent Assignment#page27.tif
source=Patent Assignment#page28.tif
source=Patent Assignment#page29.tif
source=Patent Assignment#page30.tif
source=Patent Assignment#page31.tif
source=Patent Assignment#page32.tif
source=Patent Assignment#page33.tif
source=Patent Assignment#page34.tif
source=Patent Assignment#page35.tif
source=Patent Assignment#page36.tif
source=Patent Assignment#page37.tif
source=Patent Assignment#page38.tif
source=Patent Assignment#page39.tif
source=Patent Assignment#page40.tif
source=Patent Assignment#page41.tif

PATENT ASSIGNMENT

THIS ASSIGNMENT OF PATENTS (this "Assignment"), including all schedules attached hereto, is made effective October 25, 2019, between BioElectron Technology Corporation, a Delaware corporation ("Assignor") and PTC Therapeutics, Inc., a Delaware corporation ("Assignee"). Assignor and Assignee may be referred to in this Assignment each as a "Party" and collectively as the "Parties."

WHEREAS, Assignor and Assignee are parties to an Asset Purchase Agreement, dated October 1, 2019 (the "Agreement"); and

WHEREAS, pursuant to the Agreement, the Parties have agreed that Assignor would transfer, or cause to be transferred, to Assignee certain patents, patent applications, utility models, design registrations and certificates of invention and other governmental grants for the protection of inventions or industrial designs (including all related continuations, continuations-in-part, divisionals, reissues and reexaminations), to the extent used or intended to be used by any member of the Seller Group in the conduct of, or otherwise related to, any of the Products or the Business, including, but not limited to, those identified on Schedule A hereto (all of the foregoing being referred to herein as the "Assigned Patents").

NOW, THEREFORE, in consideration of the execution of the Agreement, the payment of the consideration stipulated in the Agreement, the mutual promises and covenants hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound thereby, the Parties agree as follows:

1. All capitalized terms not otherwise defined herein, as used in this Assignment, shall have the respective meanings ascribed to such terms in the Agreement.
2. Assignor hereby assigns to Assignee all right, title and interest in, to and under the Assigned Patents, including (i) all rights in applications anywhere in the world claiming priority thereto, (ii) all rights to claim priority thereto, (iii) all reissues, continuations, continuations-in-part, divisionals, reexaminations and foreign equivalents thereof, (iv) all letters patent that may be granted on any of the patent applications included therein, (v) all income and payments now or hereafter due or payable with respect thereto, (vi) all causes of action in law or equity relating thereto, and (vii) all rights to sue, counterclaim and recover for past, present and future infringement of the rights assigned, the same to be held and enjoyed by Assignee, its successors and assigns at least as fully and entirely as the same would have been held and enjoyed by Assignor had no sale and assignment of said Assigned Patents been made.
3. Assignor further agrees to execute such further documents reasonably required by Assignee to secure and enforce the rights granted to Assignee under this Assignment.
4. Assignee may record this Assignment with the United States Patent and Trademark Office ("USPTO") and with comparable offices in other jurisdictions throughout the world. All costs associated with any such registrations or recordations shall be paid by Assignee. Assignor hereby authorizes and requests the Commissioner for Patents of the USPTO, and any Official of any country or countries foreign to the United States whose duty is to record documents evidencing

ownership of patents and patent applications to record Assignee as owner of the Patents, including any reissues, continuations, continuations-in-part, divisionals, or reexaminations thereof and foreign equivalents thereto.

5. Assignor hereby authorizes and requests the Commissioner for Patents of the USPTO, and any Official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue all letters patent related to the Assigned Patents to the Assignee, its successors, legal representatives, and assigns, in accordance with the terms of this Assignment.

6. This Assignment shall inure to the benefit of and be binding upon the Parties and their respective successors and permitted assigns.

7. This Assignment shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of Delaware.

8. This Assignment may be executed in counterparts, each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each Party hereto and delivered to the other Party, it being understood that each Party need not sign the same counterpart. This Assignment may be executed and delivered by facsimile or by an electronic scan delivered by electronic mail.

9. Each of the Assignor and Assignee by its execution of this Assignment hereby acknowledges and agrees that neither the representations and warranties, nor the rights and remedies of the parties under the Agreement shall be deemed to be enlarged, diminished, modified or altered in any way by this Assignment. In the event of any conflict between the Agreement and this Assignment, the terms of the Agreement shall control.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the Parties have caused this Assignment to be executed by their duly authorized officers as of the date first written above.

BIOELECTRON TECHNOLOGY
CORPORATION

By 
Name: Matthew Klein
Title: Chief Executive Officer

ACCEPTED:

PTC THERAPEUTICS, INC.

By: _____
Name: Stuart W. Peltz
Title: Chief Executive Officer

[Signature Page to Patent Assignment]


IN WITNESS WHEREOF, the Parties have caused this Assignment to be executed by their duly authorized officers as of the date first written above.

BIOELECTRON TECHNOLOGY
CORPORATION

By: _____
Name: Matthew Klein
Title: Chief Executive Officer

ACCEPTED:

PTC THERAPEUTICS, INC.

By:  _____
Name: Stuart W. Peltz
Title: Chief Executive Officer

[Signature Page to Patent Assignment]

Schedule A

(see attached)

[Schedule A to Patent Assignment --- Page 1]

ActiveUS 176470133v.2

BioElectron Patent Docket ² (as of 10/23/2019)

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001AT	AT	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001AT-DIV	AT	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001AT-DIV3	AT	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001BE	BE	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001BE-DIV	BE	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001BE-DIV3	BE	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001BG	BG	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CA	CA	2610152	11/28/2007	2610152	4/10/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS

² EP and EA cases that have entered validation stage are shown in *italics*.

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001CA-DIV	CA	2996149	2/23/2018			REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CH	CH	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CH-DIV	CH	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CH-DIV3	CH	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CY	CY	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CZ	CZ	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001CZ-DIV	CZ	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001DE	DE	6784530.5	11/21/2007	602006044033.2	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001DE-DIV	DE	12162555.2	3/30/2012	602006051548.0	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001DE-DIV3	DE	12195108.1	11/30/2012	602006057172.0	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001DK	DK	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001DK-DIV	DK	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001DK-DIV3	DK	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001EA	EA	200702622	12/25/2007	016226	03/30/2012	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001EA-DIV	EA	201101668	12/22/2011			REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001EE	EE	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001EP	EP	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001EP-DIV	EP	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED-0001EP-DIV3	EP	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001ES	ES	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001ES-DIV	ES	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001ES-DIV3	ES	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001FI	FI	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001FI-DIV	FI	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001FI-DIV3	FI	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001FR	FR	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001FR-DIV	FR	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001FR-DIV3	FR	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001GB	GB	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001GB-DIV	GB	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001GB-DIV3	GB	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001GR	GR	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001GR-DIV	GR	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001GR-DIV3	GR	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001HK-DIV	HK	12113337.1	3/11/2008	1173364	11/3/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001HU	HU	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001HU-DIV	HU	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001IE	IE	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001IE-DIV	IE	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001IE-DIV3	IE	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS

PATENT

REEL: 053210 FRAME: 0047

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001IS	IS	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001IT	IT	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001IT-DIV	IT	12162555.2	3/30/2012	502017000034214	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001IT-DIV3	IT	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001JP-DIV2	JP	2013-030630		5631428	10/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001LT	LT	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001LU	LU	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001LU-DIV	LU	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001LV	LV	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001MC	MC	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001MX	MX	MXA2007015006	11/28/2007	304532	10/23/2012	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001MX-DIV	MX	MXA2010011492	10/19/2010	305574	11/27/2012	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001MX-DIV2	MX	MXA2012009599	8/17/2012	359292	9/24/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001NL	NL	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001NL-DIV	NL	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001NL-DIV3	NL	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001PL	PL	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001PL-DIV	PL	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001PL-DIV3	PL	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001PT	PT	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS

PATENT

REEL: 053210 FRAME: 0049

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001PT-DIV	PT	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001RO	RO	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001RO-DIV	RO	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001RU	RU	200702622	12/25/2007	16226	3/30/2012	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SE	SE	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SE-DIV	SE	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SE-DIV3	SE	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SI	SI	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SI-DIV	SI	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001SK	SK	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0001SK-DIV	SK	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001TR	TR	6784530.5	11/21/2007	1888059	12/17/2014	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001TR-DIV	TR	12162555.2	3/30/2012	2471530	1/11/2017	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001TR-DIV3	TR	12195108.1	11/30/2012	2564843	12/26/2018	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATIONS OF ENERGY BIOMARKERS
ED0001US	US	11/445,582	6/1/2006	9447006	9/20/2016	REDOX -ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0001US-DIV	US	12/777,179	5/10/2010			REDOX -ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002CA	CA	2622523	3/13/2008	2622523	2/18/2014	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002EA	EA	200800819	9/15/2006	21818	9/30/2015	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002EP	EP	6814749.5	2/1/2008			TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002HK	HK	8107428.9	7/7/2008			TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0002JP-DIV	JP	2013-098528	5/8/2013	5999816	9/9/2016	CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
						TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002MX	MX	MXA2008003510	3/12/2008	265350	3/23/2009	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
						TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002RU	RU	200800819		21818	9/30/2015	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
						TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0002US	US	11/521,887	9/15/2006	7432305	10/7/2008	TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
						TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0004AU	AU	2003287250		2003287250	1/28/2010	IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES
ED0004JP	JP	2005-502210		4599292	10/1/2010	IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES
ED0004US	US	10/696,752	10/29/2003	7491312	2/17/2009	IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES
ED0005CA	CA	2635280	6/25/2008	2635280	12/12/2017	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
						SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005CH-DIV	CH	10015055.6	11/26/2010	2332534	11/14/2018	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0005CH-DIV3	CH	13163805.8	4/15/2013	2617418	11/22/2017	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005DE	DE	7751472.7	6/23/2008	602007030011.8	4/24/2013	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005DE-DIV	DE	10015055.6	11/26/2010	602007056853.6	11/14/2018	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005DE-DIV3	DE	13163805.8	4/15/2013	602007053175.6	11/22/2017	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005EA	EA	200801623		19675	5/30/2014	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005EP	EP	7751472.7	6/23/2008	1986636	4/24/2013	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005EP-DIV	EP	10015055.6	11/26/2010	2332534	11/14/2018	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005EP-DIV3	EP	13163805.8	4/15/2013	2617418	11/22/2017	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0005FR-DIV	FR	10015055.6	11/26/2010	2332534	11/14/2018	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005FR-DIV3	FR	13163805.8	4/15/2013	2617418	11/22/2017	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005GB	GB	7751472.7	6/23/2008	1986636	4/24/2013	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005GB-DIV	GB	10015055.6	11/26/2010	2332534	11/14/2018	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005GB-DIV3	GB	13163805.8	4/15/2013	2617418	11/22/2017	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005HK	HK	9103886.2	4/27/2009	1124552	1/30/2014	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005IT	IT	7751472.7	6/23/2008	1986636	4/24/2013	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005JP	JP	2008-556437		5374162	9/27/2013	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0005MX	MX	MXA2008007631	6/12/2008	310729	6/21/2013	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005MX-DIV	MX	MXA2012000147	1/2/2012	330023	5/13/2015	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005RU	RU	200801623		19675	5/30/2014	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005US	US	11/710,042	2/22/2007	9278085	3/8/2016	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0005US-CON	US	14/983,330	12/29/2015	9932286	4/3/2018	SIDE-CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
ED0009US	US	10/020,450	12/14/2001	7034054	4/25/2006	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA USING NON-ALPHA TOCOPHEROLS
ED0013US	US	10/941,125	9/15/2004	7514461	4/7/2009	CHROMAN DERIVATIVES
ED0013US-DIV2	US	13/245,741	9/26/2011	8791155	7/29/2014	CHROMAN DERIVATIVES
ED0014CA	CA	2580584	3/16/2007	2580584	7/28/2015	TREATMENT OF MITOCHONDRIAL DISEASES
ED0015US	US	10/941,121	9/15/2004	7470798	12/30/2008	7,8-BICYCLOALKYL-CHROMAN DERIVATIVES
ED0015US-DIV	US	12/277,083	11/24/2008	7875607	1/25/2011	7,8-BICYCLOALKYL-CHROMAN DERIVATIVES
ED0016AT	AT	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONVYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0016BE	BE	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016CA	CA	2704473	5/25/2010	2704473	10/4/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016CH	CH	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016CH-DIV	CH	15190273.1	10/16/2015	3018122	10/10/2018	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016CZ	CZ	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016DE	DE	8847883.9	5/25/2010	602008042077.9	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016DE-DIV	DE	15190273.1	10/16/2015	602008057411.3	10/10/2018	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016DK	DK	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016EA	EA	201000756	6/4/2010	28911	1/31/2018	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016EA-DIV	EA	201791981	10/6/2017			4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016EP	EP	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016EP-DIV	EP	15190273.1	10/16/2015	3018122	10/10/2018	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016EP-DIV2	EP	18198941.9	10/5/2018			4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016ES	ES	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016FI	FI	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016FR	FR	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0016FR-DIV	FR	15190273.1	10/16/2015	3018122	10/10/2018	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016GB	GB	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016GB-DIV	GB	15190273.1	10/16/2015	3018122	10/10/2018	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016GR	GR	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016HK	HK	10110222.7	11/1/2010	1143804	6/17/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016HK-DIV2	HK	19129816.5	9/18/2019			4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016HU	HU	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016IE	IE	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016IT	IT	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016JP	JP	2010-532329	4/28/2010	5755881	6/5/2015	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016JP-DIV4	JP	2019-091932	5/15/2019			4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016LU	LU	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016MX	MX	MXA2010004622	4/27/2010	314400	10/21/2013	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016MX-DIV	MX	MXA2013012276	10/21/2013	338572	4/22/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016MX-DIV2	MX	MXA2016005111	4/20/2016			4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016NL	NL	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0016NO	NO	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016PL	PL	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016PT	PT	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016RO	RO	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016RU	RU	201000756	6/4/2010	28911	1/31/2018	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016SE	SE	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016SI	SI	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016SK	SK	8847883.9	5/25/2010	2220030	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016TR	TR	8847883.9	5/25/2010	2016/04/48	1/13/2016	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016US	US	12/264,838	11/4/2008	7968746	6/28/2011	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016US-CON	US	13/924,363	6/21/2013	9169196	10/27/2015	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016US-CON2	US	15/374,916	12/9/2016	10167251	1/1/2019	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016US-CON3	US	16/228,657	12/20/2018			4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016US-DIV	US	13/110,830	5/18/2011	8519001	8/27/2013	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0016US-DIV2	US	14/829,534	8/18/2015	9546132	1/17/2017	4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0018CA	CA	2708961	6/10/2010	2708961	3/28/2017	(HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0018EA	EA	201001119		23618	6/30/2016	(HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0018EP	EP	9700856.9	7/26/2010			(HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0018HK	HK	11102697.9	3/17/2011			(HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0018JP	JP	2010-542313	7/7/2010	5649454	11/21/2014	(HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0018RU	RU	201001119		23618	6/30/2016	(HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0018US	US	12/811,694	10/8/2010	8952071	2/10/2015	(HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0018US-DIV	US	14/586,516	12/30/2014	9486435	11/8/2016	(HET) ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
ED0019CA	CA	2717734	9/3/2010			2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0019DE	DE	9717547.5	9/21/2010	602009054853.0	10/3/2018	2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0019EP	EP	9717547.5	9/21/2010	2262508	10/3/2018	2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0019FR	FR	9717547.5	9/21/2010	2262508	10/3/2018	2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0019GB	GB	9717547.5	9/21/2010	2262508	10/3/2018	2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0019JP	JP	2010-549855	9/3/2010	5710277	3/13/2015	2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0019US	US	12/919,007	10/18/2010	8716527	5/6/2014	2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0019US-DIV	US	14/223,842	3/24/2014	9090576	7/28/2015	2-SUBSTITUTED-P-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0020CA	CA	2717741	9/3/2010	2717741	4/3/2018	TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0020JP-DIV	JP	2014-016459	1/31/2014	6131200	4/21/2017	TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS
ED0023CA	CA	2729227	12/23/2010	2729227	5/22/2018	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023DE	DE	97708820	1/12/2011	602009030208.6	3/25/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023EP	EP	97708820	1/12/2011	2303824	3/25/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023GB	GB	97708820	1/12/2011	2303824	3/25/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023IT	IT	9770882	1/12/2011	2303824	3/25/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023JP	JP	2011-516536	12/24/2010	5798481	8/28/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023US	US	12/997,869	2/15/2011	8716486	5/6/2014	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0023US-DIV	US	14/223,932	3/24/2014	9073873	7/7/2015	2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0026BR	BR	PI0918139-3	3/10/2011			TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026CA	CA	2736250	3/4/2011	2736250	12/20/2016	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026EP	EP	9792325.4	4/6/2011			TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0026HK	HK	11114109.6	1/20/2012			TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026JP-DIV2	JP	2015-055908	3/19/2015	6259410	12/15/2017	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026JP-DIV4	JP	2017-076681	4/7/2017			TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026JP-DIV5	JP	2018-116995	6/20/2018			TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026MX	MX	MXA2011002318	3/1/2011	319696	4/25/2014	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026MX-DIV	MX	MXA2014004966	4/24/2014	363223	3/15/2019	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US	US	12/555,700	9/8/2009	8314153	11/20/2012	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US-CON	US	14/605,937	1/26/2015	9399612	7/26/2016	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US-CON2	US	15/208,549	7/12/2016	10105325	10/23/2018	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US-CON3	US	16/165,985	10/19/2018			TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US-DIV	US	13/651,330	10/12/2012	8653144	2/18/2014	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0026US-DIV2	US	14/155,288	1/14/2014	8969420	3/3/2015	TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
ED0028CH	CH	9821111.3	5/4/2011	2362726	8/8/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0028DE	DE	9821111.3	5/4/2011	602009053/93.8	8/8/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0028EP	EP	9821111.3	5/4/2011	2362726	8/8/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0028FR	FR	9821111.3	5/4/2011	2362726	8/8/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0028GB	GB	9821111.3	5/4/2011	2362726	8/8/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0028US	US	13/123,496	5/26/2011	10039722	8/7/2018	TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0028US-CON	US	16/020,882	6/27/2018			TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
ED0029US-CON3	US	16/213,927	12/7/2018			TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES
ED0030AT	AT	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES
ED0030AT-DIV	AT	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES
ED0030BE	BE	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES
ED0030BE-DIV	BE	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES
ED0030BR	BR	PI0920414-8	4/27/2011	PI0920414-8	5/22/2018	PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0030CA	CA	2741767	4/27/2011	2741767	9/12/2017	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030CA-DIV	CA	2974482	7/25/2017			PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030CH	CH	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030CH-DIV	CH	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030CN	CN	200980152635.0	6/27/2011	102264730	4/13/2016	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030CN-DIV	CN	201610142967.2	3/14/2016	105753829	2/1/2019	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030CZ-DIV	CZ	15175938.8	7/8/2018	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030DE	DE	9824070.8	5/23/2011	602009033072.1	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030DE-DIV	DE	15175938.8	7/8/2015	602009055191.4	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030DK	DK	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030DK-DIV	DK	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030EA	EA	201100699	5/27/2011	26417	4/28/2017	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030EA-DIV	EA	201692046	11/10/2016			PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030EP	EP	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030EP-DIV	EP	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030EP-DIV2	EP	18200523.1	10/15/2018			PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0030ES	ES	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030ES-DIV	ES	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030FI-DIV	FI	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030FR	FR	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030FR-DIV	FR	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030GB	GB	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030GB-DIV	GB	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030GR-DIV	GR	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030HK	HK	12101813.9	2/23/2012	1161876	12/18/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030HK-DIV	HK	16107746.4	7/4/2016	1219718	8/30/2019	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030HU-DIV	HU	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030ID	ID	W00201101700	5/11/2011	IDP0040634	3/24/2016	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030IE	IE	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030IE-DIV	IE	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030IN	IN	3303CHENP2011	5/13/2011	298847	7/13/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030IN-DIV	IN	201848006829	2/22/2018			PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0030IT	IT	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030IT-DIV	IT	15175938.8	7/8/2015	502018000038621	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030JP	JP	2011-534678	6/14/2011	5775459	7/10/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030JP-DIV	JP	2014-177733	9/2/2014	6001025	9/9/2016	PROCESS FOR ENRICHMENT AND ISOLATION OF ALPHA- TOCOTRIENOL FROM NATURAL EXTRACTS
ED0030JP-DIV3	JP	2018-108448	6/6/2018			PROCESS FOR ENRICHMENT AND ISOLATION OF ALPHA- TOCOTRIENOL FROM NATURAL EXTRACTS
ED0030JP-DIV4	JP	2019-008496	1/22/2019			PROCESS FOR ENRICHMENT AND ISOLATION OF ALPHA- TOCOTRIENOL FROM NATURAL EXTRACTS
ED0030LU-DIV	LU	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030MX	MX	MXA2011004440	4/27/2011	311491	7/18/2013	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030MY	MY	P12011001873	4/27/2011	157119	5/13/2016	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030MY-DIV	MY	P12014003438	12/12/2014			PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030MY-DIV2	MY	P12018002729	12/28/2018			PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030NL	NL	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030NL-DIV	NL	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030NO-DIV	NO	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030PL	PL	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030PL-DIV	PL	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0030PT	PT	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030PT-DIV	PT	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030RO-DIV	RO	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030RU	RU	201100699	5/27/2011	26417	4/28/2017	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030SE	SE	9824070.8	5/23/2011	2362875	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030SE-DIV	SE	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030SG	SG	201103008-7		170993	5/6/2014	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030SI-DIV	SI	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030SK-DIV	SK	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030TR	TR	9824070.8	5/23/2011	2015/14511	8/19/2015	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030TR-DIV	TR	15175938.8	7/8/2015	2963006	10/17/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030US	US	12/606,923	10/27/2009	8106223	1/31/2012	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030US- CON	US	13/358,451	1/25/2012	8575369	11/5/2013	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030US- CON3	US	15/068,452	3/11/2016	10071978	9/11/2018	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0030US-DIV	US	16/127,102	9/10/2018			PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
ED0031BR	BR	P1010133771	10/28/2011			FORMULATION OF TOCOTRIENOL QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0034AT	AT	10747777	3/19/2012	AT-E0966731	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034AU	AU	2010286704	3/1/2012	2010286704	10/20/2016	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034BE	BE	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034BR	BR	112012004167-3	2/24/2012			METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034CA	CA	2772294	2/24/2012	2772294	8/21/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034CH	CH	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034CN	CN	201080048363.2		102647981	9/28/2016	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034CZ	CZ	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034DE	DE	10747777	3/19/2012	602010048348.7	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034DK	DK	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034EA	EA	201200355		28677	12/29/2017	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034EP	EP	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034ES	ES	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034FI	FI	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034FR	FR	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034GB	GB	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0034GR	GR	10747777	3/19/2012	20180400845	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034HU	HU	10747777	3/19/2012	1815867	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034IE	IE	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034IT	IT	10747777	3/19/2012	502018000012377.0	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034JP	JP	2012-526918	2/23/2012	5785546	7/31/2015	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034LU	LU	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034MX	MX	MXA2012002374		337990	3/30/2016	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034NL	NL	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034NO	NO	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034PL	PL	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034PT	PT	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034RO	RO	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034RU	RU	201200355		28677	12/29/2017	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034SE	SE	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034SI	SI	10747777	3/19/2012	P-201031644	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0034SK	SK	10747777	3/19/2012	2470168	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0034TR	TR	10747777	3/19/2012	2018/05682	1/31/2018	METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
ED0040AT	AT	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040BE	BE	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040BR	BR	PI10133763	10/28/2011			TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040CA	CA	2777479	10/27/2011	2777479	10/17/2017	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040CH	CH	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040CZ	CZ	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040DE	DE	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040DK	DK	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040EA	EA	201101575	11/25/2011	31126	11/30/2018	TREATMENT OF DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040EP	EP	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0040ES	ES	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040FI	FI	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040FR	FR	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040GB	GB	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040GR	GR	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040HU	HU	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040IE	IE	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040IT	IT	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040LU	LU	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040MX	MX	MXA2011011309	10/26/2011	336800	2/2/2016	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES

PATENT

REEL: 053210 FRAME: 0070

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0040NL	NL	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040NO	NO	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040PL	PL	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040PT	PT	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040RO	RO	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040RU	RU	201101575	11/25/2011	31126	11/30/2018	TREATMENT OF DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040SE	SE	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040SI	SI	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040SK	SK	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040TR	TR	10715650.7	11/17/2011	2424495	1/17/2018	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0040US-CON	US	13/859,592	4/9/2013	9370496	6/21/2016	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0040US-CON2	US	15/178,423	6/9/2016	10195161	2/5/2019	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
ED0044AU	AU	2011285619	2/16/2013	2011285619	3/16/2017	TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES
ED0044JP	JP	2013-523342	2/5/2013	6045494	11/25/2016	TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES
ED0045AU	AU	2011245384	11/14/2012	2011245384	8/18/2016	FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0045JP	JP	2013-508167	10/25/2012	5902673	3/18/2016	FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0045JP-DIV	JP	2016-046881	3/10/2016	6266674	1/5/2018	FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0045MX	MX	MXA2012012518		337594	3/11/2016	FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0045MX-DIV	MX	MXA2015010910	8/21/2015			FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0045MY	MY	PI2012004738	10/25/2012			FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0045ZA	ZA	201208535	11/13/2012	201208535	6/29/2016	FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
ED0048US	US	14/124,671	4/30/2014	9464016	10/11/2016	CATECHOL DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
ED0051EP	EP	12807735.1	2/5/2014			TREATMENT OF METHYLMALONIC ACIDURIA, ISOVALERIC ACIDURIA, AND OTHER ORGANIC ACIDURIAS WITH TOCOTRIENOL QUINONE
ED0051JP	JP	2014-519307	1/3/2014			TREATMENT OF METHYLMALONIC ACIDURIA, ISOVALERIC ACIDURIA, AND OTHER ORGANIC ACIDURIAS WITH TOCOTRIENOL QUINONE
ED0051US-CON	US	16/019,363	6/26/2018			TREATMENT OF METHYLMALONIC ACIDURIA, ISOVALERIC ACIDURIA, AND OTHER ORGANIC ACIDURIAS WITH TOCOTRIENOL QUINONES

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0054CA	CA	2842486	1/20/2014			METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054EP	EP	12814970.5	2/12/2014			METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054JP-DIV	JP	2017-005308	1/16/2017	6568880	8/9/2019	METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054US	US	14/233,734	5/19/2014	9162957	10/20/2015	METHODS FOR OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054US-CON	US	14/850,855	9/10/2015	9567279	2/14/2017	METHODS FOR OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054US-CON2	US	15/411,861	1/20/2017	10029971	7/24/2018	METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0054US-CON3	US	16/040,281	7/19/2018	10202325	2/12/2019	METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
ED0055JP	JP	2015-531249	3/5/2015	6393684	8/31/2018	MODULATION OF REDOX STATUS OF INDIVIDUALS
ED0056CA	CA	2906150	9/11/2015			RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0056US	US	13/837,872	3/15/2013	9296712	3/29/2016	RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0056US-CIP	US	14/776,683	9/14/2015	9670170	6/6/2017	RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0058US-CIP	US	14/776,688	9/14/2015	9868711	1/16/2018	PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0059MX	MX	MXA2015016014				CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0060CA	CA	2906145	9/11/2015			ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0060HK	HK	16108427.8	7/18/2016			ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0060US	US	14/776,678	9/14/2015	10189830	1/29/2019	ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0065CA	CA	2883882	3/6/2015			BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS
ED0065US	US	14/426,135	3/4/2015	9629815	4/25/2017	BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS
ED0078AU	AU	2015364640	7/6/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078BR	BR	112017012988-4	6/16/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078CA	CA	2971252	6/15/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078CN	CN	201580076205.0	8/15/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078EP	EP	15820968.4	7/7/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078HK	HK	17111114.9	10/31/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0078IL	IL	252953	6/15/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078IN	IN	201717024682	7/12/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078JP	JP	2017-532088	6/15/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078KR	KR	10-2017-7019399	7/12/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078MX	MX	MX/a/2017/008063	6/16/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078NZ	NZ	733528	7/6/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078RU	RU	2017124714	7/12/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078US	US	15/536,603	6/15/2017	10251847	4/9/2019	POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078US-CON2	US	16/354,070	3/14/2019			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0078ZA	ZA	2017/04639	7/10/2017			POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE
ED0096AU	AU	2016369616	6/18/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0096CA	CA	3008849	6/15/2018			BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
						FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0096CN	CN	201680082001.2	8/16/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0096EP	EP	16822869	7/4/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0096HK	HK	19122775	4/23/2019			FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0096IN	IN	201817026571	7/17/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0096JP	JP	2018-531554	6/15/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0096MX	MX	MX/a/2018/007389	6/15/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0096US	US	16/063,201	6/15/2018			FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
						BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS
ED0097EP	EP	15820772	7/7/2017			METHODS FOR CHIRAL RESOLUTION OF TROLOX
ED0099EP	EP	16826530.4	7/4/2018			IMPROVED METHODS FOR ENRICHING ALPHA-TOCOTRIENOL FROM MIXED TOCOL COMPOSITIONS
ED0099IN	IN	201817026439	7/16/2018			IMPROVED METHODS FOR ENRICHING ALPHA-TOCOTRIENOL FROM MIXED TOCOL COMPOSITIONS
ED0099JP	JP	2018-531506	6/15/2018			IMPROVED METHODS FOR ENRICHING ALPHA-TOCOTRIENOL FROM MIXED TOCOL COMPOSITIONS
ED0099US	US	16/063,035	6/15/2018			IMPROVED METHODS FOR ENRICHING ALPHA-TOCOTRIENOL FROM MIXED TOCOL COMPOSITIONS
ED0103CA	CA	3011293	7/11/2018			TOCOPHEROL AND TOCOTRIENOL QUINONE DERIVATIVES FOR INCREASING THIOSULFATE LEVELS OR DECREASING HYDROGEN SULFIDE LEVELS
ED0103JP	JP	2018-555447	7/11/2018			TOCOPHEROL AND TOCOTRIENOL QUINONE DERIVATIVES FOR INCREASING THIOSULFATE LEVELS OR DECREASING HYDROGEN SULFIDE LEVELS
ED0116US	US	16/345,677	4/26/2019			METHODS FOR ANALYZING P-HYDROQUINONE LEVELS AND RATIOS
ED0117CN	CN	201780070427.0	5/14/2019			2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-ONE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF CROSS REFERENCE TO RELATED APPLICATIONS
ED0117EP	EP	17817338.1	5/24/2019			2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-ONE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF CROSS REFERENCE TO RELATED APPLICATIONS
ED0117JP-PC	JP	2019-524868	5/13/2019			2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-ONE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF CROSS REFERENCE TO RELATED APPLICATIONS

Client Ref	Country Code	Application Number	Filing Date	Patent Number	Issue Date	Title
ED0117US	US	16/349,940	5/14/2019			2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-ONE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF CROSS REFERENCE TO RELATED APPLICATIONS
ED0121PCT	WO	PCT/US2018/027682	4/14/2018			METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND OXIDATIVE STRESS
ED0121US	US	16/605,192	10/14/19			METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND OXIDATIVE STRESS
ED0123US	US	15/675,364	8/11/2017			Distributed Systems and Methods for Learning About a Bioprocess from Redox Indicators and Local Conditions
ED0123US-CIP	US	15/702,885	9/13/2017			Redox-related context adjustments to a reference bioprocess model used in learning system and methods based on redox indicators
ED0123US-CIP2	US	15/785,415	10/16/2017			Redox-related context adjustments to a bioprocess monitored by learning systems and methods based on redox indicators

PATENT

REEL: 053210 FRAME: 0078

RECORDED: 07/14/2020